Description du projet
Nouveaux médicaments contre la maladie de Parkinson
La maladie de Parkinson (MP) est une neurodégénérescence progressive qui se caractérise par des tremblements, une rigidité et une altération des mouvements. La MP affecte les neurones producteurs de dopamine du cerveau de millions de personnes dans le monde. Les options de traitement disponibles sont limitées, le médicament le plus puissant étant un précurseur de la dopamine, la lévodopa. Le projet IRL790, financé par l’UE, vise à augmenter la gamme de médicaments disponibles contre la MP et à réduire les mouvements erratiques et les psychoses chez les patients. Les chercheurs ont tenu compte de la complexité des maladies du système nerveux central pour concevoir deux médicaments différents qui donnent des résultats prometteurs dans le cadre d’essais cliniques préliminaires.
Objectif
This project’s goal is to develop a successful treatment that combats severe motor and psychotic symptoms in Parkinson’s disease (PD). PD is a debilitating neurodegenerative disorder affecting > 6 million people worldwide. It’s the neurological disorder with the highest increase in death rates, prevalence, and disability-adjusted life-years (DALYs). Levodopa, introduced more than 50 years ago, remains the most prescribed treatment for the symptomatic relief of PD, although its long-term use leads to the development of motor complications, i.e. levodopa-induced dyskinesia (PD-LIDs).
IRLAB aims to address the challenge in PD treatment by clinically validating its novel compound, IRL790, aimed at reducing symptoms of PD-LIDs and Parkinson’s disease psychosis. IRLAB’s programme is based on its proprietary drug discovery platform, Integrative Screening Process (ISP), which captures a better understanding of complexities of CNS-related diseases, such as PD, and yields drug candidates with superior chance of success in the clinic.
IRLAB’s therapeutic will improve intervention outcomes for PD patients in two indications. Its safety and tolerability have been validated in Phase I clinical trials and its therapeutic efficacy in PD-LIDs is being evaluated in an ongoing Phase II study. Results are expected 2018. Besides medical benefits to patients, IRL790 has also the potential to bring cost-savings to healthcare providers by effectively reducing the Parkinson’s disease burden.
Generation of high quality clinical data will improve IRLAB’s opportunities for out-licensing. We plan to apply for SME grant to accelerate clinical developmental and take IRL790 through a Phase II study in PD psychosis. This way, we will out-license and market the drug sooner and for two indications (PD-LIDs and PD psychosis) simultaneously. IRLAB has an established business development contact network and have gained trust of international healthcare investors and national innovation funding bodies.
Champ scientifique
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
413 46 GOTEBORG
Suède
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.